1. Introduction {#s0005}
===============

It has been long debated whether schizophrenia and schizoaffective disorder represent a single disorder or two distinct conditions ([@bb0055]; [@bb0230]). These syndromes share psychotic symptoms, but schizoaffective disorder involves a concurrent mood disorder and does not require evidence of a decline in role functioning. Schizoaffective disorder was retained as a separate diagnostic entity in the *Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition* (*DSM-5*) ([@bb0020]) and in the *International Statistical Classification of Diseases and Related Health Problems, Tenth Revision* (*ICD-10*) ([@bb0340]). However, its validity as a distinct form of psychotic illness remains in question ([@bb0180]; [@bb0195], [@bb0190]).

Cognitive performance may provide a way of "carving nature at its joints" within the schizophrenia spectrum and is of key importance in relation to functional outcome ([@bb0205]) and the search for candidate endophenotypes of psychosis ([@bb0145]). A series of studies have found significantly more cognitive impairment in schizophrenia than in schizoaffective disorder ([@bb0040]; [@bb0115]; [@bb0140]; [@bb0150]; [@bb0160]; [@bb0215]; [@bb0225]; [@bb0300]; [@bb0315]), but many others report minimal or no differences between these groups ([@bb0010]; [@bb0030]; [@bb0080]; [@bb0090]; [@bb0105]; [@bb0110]; [@bb0120]; [@bb0165]; [@bb0235]; [@bb0250]; [@bb0255]; [@bb0265]; [@bb0270]; [@bb0280]; [@bb0285]; [@bb0290]; [@bb0295]; [@bb0305]; [@bb0320]). Patients with schizoaffective disorder exhibit a pattern of cognitive impairment that is similar to the findings obtained in patients with schizophrenia, but distinct from those with major depression and bipolar disorder ([@bb0005]; [@bb0045]; [@bb0220]). A meta-analysis concluded that cognitive data failed to support performance differences between patients with schizophrenia and schizoaffective disorder ([@bb0035]).

Social cognition and its correlated neural circuits have emerged recently as a biobehavioural domain that is distinct from emotionally "cold" standard cognitive performance ([@bb0245]). This domain may provide new insights and incremental validity in predicting functional outcome ([@bb0065]) and inform the search for more refined behavioural endophenotypes of psychosis ([@bb0145]). Components of social cognition include emotion perception and regulation and "theory of mind," or the ability to imagine the psychological states and experiences of others ([@bb0125]). The small relevant literature is inconsistent, with some reports that schizoaffective disorder patients outperform those with schizophrenia on theory of mind tasks ([@bb0050]; [@bb0090]; [@bb0310]). In contrast, other studies indicate no significant differences between groups in terms of theory of mind ([@bb0130]; [@bb0165]) or emotion perception ([@bb0090]). It is noteworthy that most studies assessed single rather than multiple domains of social cognition, excluded non-psychiatric control participants and failed to consider both social and non-social aspects of cognition.

Behavioural studies have been complemented by advances in social and affective neuroscience including the description and analysis of an intrinsic social brain network (SBN) ([@bb0075]). This network links a series of pre- and medial frontal and temporal - parietal lobe regions that appear to mediate social and emotional processing ([@bb0075]). Structural and functional magnetic resonance neuroimaging studies have shown that schizophrenia and schizoaffective disorder share cerebral gray and white matter reductions and altered activation patterns relative to control values ([@bb0220]). Regions most affected include several frontal, cingulate and temporal lobe structures implicated in the SBN ([@bb0170]). However, it is not known whether SBN abnormalities occur preferentially or more severely in people with schizophrenia relative to schizoaffective disorder or whether they are common neurobiological features in patients with psychosis. If SBN abnormalities are shared, this would further undermine the validity of psychosis variants like schizophrenia and schizoaffective disorder.

We asked whether patients with diagnoses of schizophrenia and schizoaffective disorder differ significantly, and to what degree, on standard cognitive performance measures, and whether social cognition and cortical thickness in regions associated with the SBN show sensitivity to the diagnostic distinction. More specifically, a multivariate approach was adopted whereby the ability of these measures to recapitulate the diagnostic classification was examined. Differences between the two diagnostic groups were of primary interest, but comparison to demographically similar non-psychiatric control participants was also carried out. This was done to determine whether the two patient groups were cognitively impaired and demonstrated cortical thinning. The results should help clarify whether these two psychosis syndromes are behaviourally and neurobiologically separable and thereby help resolve the underlying issue of disease heterogeneity in the schizophrenia spectrum.

2. Materials and methods {#s0010}
========================

2.1. Participants {#s0015}
-----------------

The clinical sample comprised 73 male and female patients who met the following criteria: 1) diagnosis of schizophrenia (*n* = 44) or schizoaffective disorder (*n* = 29) confirmed by the Structured Clinical Interview for *DSM-IV-TR* Axis I Disorders ([@bb0085]); 2) outpatient status; 3) history free of developmental or learning disability; 4) age 18--65; 5) history free of neurological or endocrine disorder; and 6) no concurrent *DSM-IV-TR* ([@bb0015]) diagnosis of substance use disorder. Participants in the non-psychiatric control group (*n* = 62) were screened for medical and psychiatric illness and history of substance abuse.

All participants were drawn from an earlier study of normal-range and impaired cognitive performance in schizophrenia. Accordingly, clinical participants were recruited from a variety of outpatient programs, but especially those with active and relatively demanding rehabilitation services focused on high-functioning patients ([@bb0155]). Settings comprised three outpatient clinics in Hamilton, Ontario, Canada: the Cleghorn Early Intervention in Psychosis Program, the Hamilton Program for Schizophrenia, and the Community Schizophrenia Service affiliated with St. Joseph\'s Healthcare. At the same time, a broad range of cognitive ability in the control sample was maximized by recruiting community participants through local newspaper and online classified advertisements, employment centers, and neighborhood organizations and agencies. Written informed consent was obtained from all participants and each received financial compensation for their time. This study was approved by the relevant institutional review boards in Hamilton and by York University in Toronto, Ontario, Canada.

2.2. Procedure and measures {#s0020}
---------------------------

### 2.2.1. Clinical and cognitive measures {#s0025}

Patients were administered the Structured Clinical Interview for *DSM-IV-TR* (SCID-I/II) ([@bb0085]) to confirm diagnosis. Symptoms were assessed with the Positive and Negative Syndrome Scale (PANSS) ([@bb0175]). Two indicators of functionality were used for patients based on information obtained from the Social and Psychiatric History Schedule ([@bb0275]): employment status (full-time, part-time, volunteer or unemployed) and living status (independent or assisted).

All participants\' premorbid intelligence was estimated using the standardized score from the Word Reading subtest of the Wide Range Achievement Test - Fourth Edition (WRAT-4) ([@bb0335]). A prorated estimate of current intellectual ability was obtained from the Vocabulary and Matrix Reasoning subtests of the Wechsler Abbreviated Scale of Intelligence (WASI) ([@bb0330]). Cognitive function was also assessed among all participants using the MATRICS Consensus Cognitive Battery (MCCB) ([@bb0260]). The MCCB includes domain measures titled Working Memory, Attention, Verbal Learning, Processing Speed, Reasoning and Problem-Solving, Visual Learning and Social Cognition and yields a composite index of overall performance. However, 86% of the composite score variance is accounted for by three domain measures: Working Memory, Visual Learning, and Processing Speed ([@bb0100]). An abbreviated composite score index comprising an average of *T* scores obtained for these domains demonstrates excellent test-retest reliability (intraclass correlation = 0.86). This composite was used as an index of general, non-social cognition in the present study.

The Reading the Mind in the Eyes test ([@bb0025]) ("Eyes test") is a widely used theory of mind task that measures the ability to infer and discriminate emotions expressed in the eye region of the face. Participants scored one point for each correct response and total possible scores range from 0 to 36. Emotion perception and regulation was assessed with the Managing Emotions subtest from the Mayer--Salovey--Caruso Emotional Intelligence Test, Version 2.0 (MSCEIT) ([@bb0240]). The ability to manage emotions is assessed by presenting a series of scenarios and asking the test-taker to identify the most adaptive ways to regulate or manage their own feelings (Emotion Management Task) and the feelings of others in these situations (Emotional Relationship Task). The MSCEIT also comprised the Social Cognition domain score in the MCCB but was analyzed separately as a social cognition index. All tests described were administered by trained graduate-level clinical psychology students and a research assistant.

### 2.2.2. MRI cortical thickness measurement {#s0030}

Participants underwent scanning with a 3.0 Tesla whole body short bore General Electric System MRI scanner with an 8-channel parallel receiver head coil at the Imaging Research Centre, St. Joseph\'s Healthcare Hamilton. A T1-weighted axial anatomical scan was acquired using a three-dimensional fast spoiled gradient recalled echo sequence with inversion recovery preparation. The anatomical image had 152 slices (2 mm thick with 1 mm overlap) with the following imaging parameters: time to repetition (TR)/echo time (TE) = 7.5/2.1 ms, TI = 450 ms, field of view (FOV) = 24 cm, matrix = 512 × 512, flip angle = 12°, receiver bandwidth (rBW) = ±62.5 kHz, and number of excitations (NEX) = 1.

The T1-weighted images collected for each participant were pre-processed in order to segment the brain and to align cortical structures across the subjects using FreeSurfer automated image analysis (version 5.1.0; <http://surfer.nmr.mgh.harvard.edu/>). Each image was inspected to correct for motion and underwent spatial and intensity normalization and skull stripping. Cortical thickness was defined as the distance between pial surface to the gray/white matter border across 160,000 vertices in both cerebral hemispheres. Subsequently each image was visually inspected by trained inspectors blind to group assignment to correct inaccuracies. Once images passed inspection, high dimensional registration was used to map them onto a spherical atlas for increased inter-subject alignment accuracy. Surface maps were smoothed with a 15 mm full-width-half-maximum Gaussian kernel.

Cortical parcellations were obtained for regions of interest (ROIs) using the methods described by Destrieux and colleagues in Freesurfer ([@bb0070]). The Destrieux atlas involves bilateral hemispheric parcellation of both gyral and sulcal structures. A total of 21 ROIs in each cerebral hemisphere were chosen for analysis based on their inclusion in the SBN as described in recent research ([@bb0075]; [@bb0135]; [@bb0200]; [@bb0210]). A visual representation of these brain regions is provided in [Fig. 1](#f0005){ref-type="fig"}.Fig. 1Social brain regions. Left: lateral and medial cortical regions associated with social network; middle and right: significant social network sub-region thinning in patient groups relative to controls after correction.Fig. 1

### 2.2.3. Statistical analysis {#s0035}

One-way analysis of variance (ANOVA) and frequency/cross-tabulation analyses were used to compare groups on continuous and categorical demographic and clinical variables respectively. Multivariate analysis of variance (MANOVA) was carried out on the cognitive/social cognitive and cortical thickness data depending on satisfaction of required assumptions. These included non-significant covariance matrix (Box\'s test) and error variance (Levene tests) inequality across groups. Overall group comparisons were followed by Bonferroni-corrected pair-wise group comparisons on individual variables. If MANOVA assumptions were not met, transformations were considered along with non-parametric ANOVA and independent groups tests (Kruskal-Wallis, Mann-Whitney). Discriminant function analysis was applied to the data to test the ability of cognitive/social cognitive performance and social brain-related cortical thickness to recapitulate and hence validate the diagnostic groups. This technique builds linear functions of continuous variables that discriminate maximally the categorical grouping variable. Given the relatively large number of variables relative to sample size and to ensure statistical economy, decision rules were applied to limit redundancy and unnecessary testing.

3. Results {#s0040}
==========

3.1. Demographic and clinical characteristics {#s0045}
---------------------------------------------

[Table 1](#t0005){ref-type="table"} provides demographic information for the three study groups and clinical statistics for patients. One-way analysis of variance (ANOVA) and frequency analysis (chi-squared) showed that the three groups did not differ significantly in terms of age, gender distribution, years of education or first language. The two patient groups did not differ significantly in the proportion taking first versus second generation anti-psychotic medication, benzodiazepines or mood stabilizers. The differing frequencies of anti-Parkinsonian medication approached (*P* = .1) but did not reach significance. Mean daily doses of the three most commonly prescribed anti-psychotic medications did not differ between patient groups (risperidone: *t*(61) = 1.32, *P* = .19; olanzapine: *t*(60) = −0.50, *P* = .62; clozapine: *t*(62) = 1.12, *P* = .27). The patient groups also did not differ significantly in the severity and duration of illness as indexed by the number of years since psychotic symptom onset or hospitalizations. Similarly, there were no differences in the severity of positive or negative symptoms and general psychopathology. However, schizoaffective disorder patients showed elevated depression scores relative to schizophrenia patients. The PANSS data suggest low-average symptom severity relative to the original normative validation study ([@bb0075]). In addition, a lower proportion of schizophrenia patients were living independently, although there were no significant differences in frequency of employment.Table 1Demographic, clinical and functional characteristics of diagnostic and comparison groups.Table 1Schizophrenia\
(*n* = 44)Schizoaffective\
(*n* = 29)Comparison\
(*n* = 62)StatisticAge (years) (SD)41.07 (11.75)41.97 (8.36)38.89 (11.55)0.95[a](#tf0005){ref-type="table-fn"}Education (years) (SD)12.81 (1.97)13.03 (2.54)12.53 (2.22)0.55[a](#tf0005){ref-type="table-fn"}Sex (% male)6455620.56[b](#tf0010){ref-type="table-fn"}First language (% English)8996941.78[b](#tf0010){ref-type="table-fn"}Antipsychotic medication1.01[b](#tf0010){ref-type="table-fn"} 2nd generation (%)6676-- 1st generation (%)1614--Cogentin (%)[f](#tf0030){ref-type="table-fn"}823--2.79[b](#tf0010){ref-type="table-fn"}Benzodiazepines (%)[g](#tf0035){ref-type="table-fn"}3946--0.28[b](#tf0010){ref-type="table-fn"}Mood stabilizers (%)[g](#tf0035){ref-type="table-fn"}1019--0.97[b](#tf0010){ref-type="table-fn"}Length of illness (years) (SD)18.22 (11.67)16.19 (8.29)--0.80[c](#tf0015){ref-type="table-fn"}Hospitalizations, mean (SD)4.90 (7.04)5.07 (7.72)----0.10[c](#tf0015){ref-type="table-fn"}PANSS T scores Positive scale, mean (SD)43.09 (7.39)40.28 (7.74)--1.56[c](#tf0015){ref-type="table-fn"} Negative scale, mean (SD)39.14 (7.04)37.59 (6.47)--0.95[c](#tf0015){ref-type="table-fn"} General scale, mean (SD)40.25 (6.92)42.24 (8.64)--1.09[c](#tf0015){ref-type="table-fn"} Depression scale, mean (SD)47.84 (10.55)55.48 (13.32)----2.73[d](#tf0020){ref-type="table-fn"}Functionality (SPHS) Independent living (%)4272--5.03[e](#tf0025){ref-type="table-fn"} Unemployed (%)4841--4.84[b](#tf0010){ref-type="table-fn"}[^1][^2][^3][^4][^5][^6][^7][^8]

3.2. Cognition and social cognition {#s0050}
-----------------------------------

Assumptions of MANOVA were examined and upheld. The findings with respect to 11 cognitive/social cognitive performance indicators are presented in [Table 2](#t0010){ref-type="table"}. The omnibus MANOVA showed a significant main effect of group (Λ = 0.59, *F*(20, 246) = 3.77, *P* \< .001). Follow-up ANOVA indicated that the groups differed significantly on 9 measures including the MCCB composite, Processing Speed, Attention/Vigilance, Verbal Learning, Visual Learning and Reasoning/Problem Solving domains. In addition, main effects of group were found for the MSCEIT (managing emotions), Reading the Mind in the Eyes test (theory of mind) and the WRAT-4 reading task, but not for WASI IQ.Table 2Cognitive/social cognitive and neural comparisons of diagnostic and comparison groups.Table 2MeasuresSchizophrenia\
(*n* = 44)\
*M(SD)*Schizoaffective\
(*n* = 29)\
*M(SD)*Comparison\
(*n* = 62)\
*M(SD)F* (2,132)*P-*valueMCCB composite (T score)35.43 (10.37)35.14 (8.87)43.35 (10.38)[a](#tf0040){ref-type="table-fn"}, [b](#tf0045){ref-type="table-fn"}10.9\<.001MCCB processing speed (T score)35.14 (11.85)33.86 (9.11)45.48 (12.77)[a](#tf0040){ref-type="table-fn"}, [b](#tf0045){ref-type="table-fn"}14.34\<.00MCCB attention/vigilance (T score)34.57 (13.42)36.48 (12.32)42.52 (1.71)[a](#tf0040){ref-type="table-fn"}4.93\<.01MCCB working memory (T score)38.25 (12.20)37.93 (12.88)43.81 (12.35)3.52\>.05MCCB verbal learning (T score)36.52 (9.88)37.76 (9.40)45.14 (10.36)[a](#tf0040){ref-type="table-fn"}, [b](#tf0045){ref-type="table-fn"}11.20\<.001MCCB visual learning (T score)32.91 (12.70)33.62 (12.27)40.77 (10.64)[a](#tf0040){ref-type="table-fn"}, [b](#tf0045){ref-type="table-fn"}7.61\<.01MCCB reasoning (T score)41.43 (9.42)41.00 (9.14)50.52 (9.42)[a](#tf0040){ref-type="table-fn"}, [b](#tf0045){ref-type="table-fn"}16.40\<.001MSCEIT managing emotions36.66 (10.86)44.31 (12.96)[a](#tf0040){ref-type="table-fn"}45.76 (12.90)[a](#tf0040){ref-type="table-fn"}7.47.001Reading the mind in the eyes (correct/36)21.20 (5.41)22.93 (4.57)25.23 (5.35)[a](#tf0040){ref-type="table-fn"}7.81\<.01WASI IQ93.59 (21.18)100.72 (20.77)101.56 (20.33)2.07.130WRAT-4 reading (standard score)88.55 (11.34)94.69 (10.55)95.27 (11.99)[a](#tf0040){ref-type="table-fn"}4.85.001[^9][^10][^11]

Post-hoc multiple comparisons adjusted with Bonferroni correction were carried out for each significant overall univariate F ratio. Findings revealed lower scores in schizophrenia patients relative to schizoaffective patients on one task: MSCEIT Managing Emotions (*t*(71) = 2.60, *P* \< .05). Schizophrenia patients scored significantly lower than the control group on the MCCB composite (*t*(104) = −3.88, *P* \< .01), Processing Speed (*t*(104) = −4.23, *P* \< .01), Attention/Vigilance (*t*(104) = −2.92 *P* \< .05), Verbal Learning (*t*(104) = −4.30, *P* \< .01), Reasoning/Problem Solving (*t*(104) --4.89, *P* \< .01)), WRAT-4 Reading (*t*(104) = −2.91 *P* \< .05)), Reading the Mind in the Eyes *(t*(104) = −3.79, *P* \< .05)) and the MSCEIT Managing Emotions task (*t*(104) = −3.82, *P* \< .05). Significant differences were found between the schizoaffective disorder and control groups on the MCCB composite (*t*(89) = −3.68, *P* \< .01), Processing Speed (t(89) = −4.40, *P* \< .01), Verbal Learning (t(89) = −3.26, *P* \< .05), Visual Learning (t(89) = −3.02, *P* \< .05) and Reasoning/Problem-Solving (t(89) = 4.03, *P* \< .01) domains.

A discriminant function analysis including the 9 cognitive/social cognitive variables with significant univariate group *F* ratios yielded two functions. The first explained 79.2% of the variance in group means, while the second explained 20.8%. In combination these functions significantly differentiated the groups (Λ = 0.62, χ^2^(18) = 60.57, *P* \< .001). However, on removal of the first function the second was only marginally significant on its own (Λ = 0.90, χ^2^(8) = 13.96, *P* = .08). The tasks that differentiated the control group from the two diagnostic groups and correlated highly with the first function were the MCCB composite (*r* = 0.60), Reasoning/Problem-Solving (*r* = 0.75), Processing Speed (*r* = 0.70), Verbal Learning (*r* = 0.62), Visual Learning (*r* = 0.51) and Attention/Vigilance (*r* = 0.41) domain scores as well as the Reading the Mind in the Eyes task (*r* = 0.50). The MSCEIT Managing Emotions (*r* = 0.61) and WRAT-4 Reading (*r* = 0.53) scores contributed to the smaller second function. Classification results revealed that these measures achieved jointly an overall accuracy of 57.0%. The cognitive/social cognitive variables correctly classified 50.0% of the schizophrenia patients, but 29.5% were incorrectly classified as having schizoaffective disorder and 20.5% as control participants. The accuracy for the schizoaffective disorder group was 55.3%, with 20.7% misclassified as schizophrenia patients and 24.1% as control group participants. Finally, 62.9% of participants in the control group were correctly classified, with 24.2% misclassified as having schizophrenia and 12.9% as having schizoaffective disorder.

3.3. Cortical thickness {#s0055}
-----------------------

Parametric analysis of variance procedures using all 42 social brain regional thickness values were not feasible due to a significant Box\'s M (1993.12, *F* (903, 26,008) = 1.20, *P* \< .001) indicating unequal covariance matrices across groups/variables, and a significant Levene tests for variance inequality. Common transformations (e.g., log, square root, reciprocal) did not alter the variance results. Therefore, a series of non-parametric (Kruskal-Wallis) ANOVAs were carried out. Following Bonferroni correction, 6 regional values remained significant across patient and control groups ([Table 3](#t0015){ref-type="table"}). Pair-wise comparisons (Mann-Whitney *U* test) revealed no significant differences between schizophrenia and schizoaffective patients on any of these regions. However, schizophrenia patients and control participants differed on all six regional cortical thickness measures and schizoaffective patients and controls differed on 5/6 comparisons.Table 3Regional cortical thickness (mm) in diagnostic and control groups.Table 3RegionSchizophrenia\
(*n* = 44)\
*M(SD)*Schizoaffective\
(*n* = 29)\
*M(SD)*Control\
(*n* = 62)\
*M(SD)*Kruskal-Wallis/*F*\
*P*Left posterior dorsal cingulate gyrus2.99 (0.22)[a](#tf0050){ref-type="table-fn"}2.96 (0.22)[a](#tf0050){ref-type="table-fn"}3.14 (0.20)\<.001Left posterior ventral cingulate gyrus2.39 (0.36)[a](#tf0050){ref-type="table-fn"}2.44 (0.34)[a](#tf0050){ref-type="table-fn"}2.64 (0.33)\<.001Left lateral fusiform gyrus2.64 (0.23)[a](#tf0050){ref-type="table-fn"}2.70 (0.16)2.83 (0.24).001Left superior temporal sulcus2.31 (0.19)[a](#tf0050){ref-type="table-fn"}2.33 (0.14)[a](#tf0050){ref-type="table-fn"}2.46 (0.15)\<.001Right posterior dorsal cingulate gyrus2.97 (0.25)[a](#tf0050){ref-type="table-fn"}2.93 (0.19)[a](#tf0050){ref-type="table-fn"}3.14 (0.23)\<.001Right superior temporal sulcus2.40 (0.24)[a](#tf0050){ref-type="table-fn"}2.43 (0.14)[a](#tf0050){ref-type="table-fn"}2.52 (0.20)\<.001Social brain average2.61 (0.19)[b](#tf0055){ref-type="table-fn"}2.63 (0.14)[b](#tf0055){ref-type="table-fn"}2.78 (0.15)\<.001[c](#tf0060){ref-type="table-fn"}[^12][^13][^14]

A SBN composite value that satisfied multivariate distribution and variance assumptions was created by averaging across the 6 significant regional thickness values identified by non-parametric analysis. This allowed for discriminant function analysis to assess classification accuracy with the SBN variable added to the 9 cognitive/social cognitive variables included in the previous analysis. The discriminant functions significantly differentiated the groups (Λ = 0.565, χ^2^ (20) = 72.88, *P* \< .001). However, the overall ability of the aggregated variables to recapitulate the diagnostic group memberships remained modest at 63.0%. Accuracy for schizophrenia was 54.5%, with 34.1% misclassified as schizoaffective disorder and 11.4% misclassified as control participants. Schizoaffective disorder patients were correctly classified with an accuracy of 58.6%, whereas 27.6% of these patients were misclassified in the schizophrenia group and 13.8% in the control group. Finally, 71.0% of participants in the control group were correctly classified as such, but 16.1% were misclassified into the schizophrenia group and 12.9% were misclassified into the schizoaffective disorder group.

4. Discussion {#s0060}
=============

The findings of this study indicate that patients with schizophrenia and schizoaffective disorder are largely indistinguishable in terms of overall cognitive performance and a specific social cognition measure, as well as in relation to brain network structures relevant to social processing and behaviour. The single exception was a finding of more proficient emotion regulation in schizoaffective disorder patients relative to those with schizophrenia. Multivariate classification analysis using the study measures demonstrated generally weak discrimination between patient groups, with better, but still modest discrimination relative to control participants. Therefore, in view of our results, the continuing diagnostic and clinical separation of these essentially overlapping syndromes is difficult to justify. The results suggest that the broad cognitive impairment regarded as intrinsic to schizophrenia also occurs in patients with psychosis who have a co-existing mood disturbance. Similarly, structural brain deficiencies in several socially-relevant regions appear to be shared across diagnoses, possibly reflecting a common underlying pathology in psychotic patients. Our data are consistent with and extend a substantial body of literature, including meta-analyses, showing that overall impairment rates, composite performance indicators, reading-based estimates of premorbid ability and aspects of social cognition, including theory of mind ([@bb0165]; [@bb0280]) as well as aspects of brain structure and physiology ([@bb0220]) all fail to distinguish clearly these syndromes.

Nevertheless, it is noteworthy that schizoaffective disorder patients outperformed those with schizophrenia on an emotion regulation task, scoring in the average range and close to control values. Recent evidence suggests that most patients with mood disorder perform normally on emotional intelligence tasks in contrast with the impairment observed in schizophrenia ([@bb0095]). Perhaps mood disturbance enhances cognitive aspects of emotion processing and makes affect regulation salient and subject to awareness in a way that is less likely to occur in non-affective psychosis. In partial support of this idea, our data showed elevated symptoms of depression in the schizoaffective disorder group relative to schizophrenia patients, implying mood disturbance as a significant aspect of clinical status at the time of testing. However, mood-related group differences are not surprising in light of the diagnostic criteria for schizoaffective disorder. Hence social cognitive performance in the schizophrenia spectrum requires additional study, especially in terms of affect regulation, because schizoaffective patients\' relative proficiency may not include theory of mind and emotion perception.

Diffuse cortical thinning is characteristic of schizophrenia and here we extend this finding to show that thickness values in several medial (posterior cingulate) and temporal (superior sulcus) regions specifically associated with social processing are reduced significantly relative to control values, but not relative to those with schizoaffective disorder. The extensive overlap between patient groups raises the possibility that thinning in social brain regions is a shared neurobiological characteristic within the schizophrenia spectrum ([@bb0325]). However, the present study did not include functional brain imaging measures of regional metabolism, blood flow or connectivity data. Nevertheless, the absence of neurobiological and cognitive validation reported in several studies and across imaging modalities ([@bb0220]) makes it difficult to maintain that separable disease processes underpin mood-based distinctions between psychotic disorders. This kind of differential validation continues to be a challenge in terms of many mental illnesses. Nevertheless, it is noteworthy that relatively high accuracy in recapitulating standard psychiatric syndromes has been achieved with some algorithms. Thus, classification rates up to 80% have been reported in relation to schizophrenia and depression using fronto-temporo-limbic MRI volumetric data ([@bb0185]). However, and consistent with our own data, recent biotyping has failed to validate schizoaffective disorder as a syndrome that is separable from schizophrenia within the psychosis spectrum ([@bb0060]).

Additional limitations to the current study should be noted. Patient sample sizes were relatively small and may have restricted our ability to detect group differences by limiting statistical power. The relative modesty of our sample sizes was a further reason for utilizing an efficient cognitive battery sensitive to psychotic illness and for focusing on a subset of cortical regions, as an exhaustive representation would have been under-powered. Moreover, the relatively small patient sample size and inclusion of patients only from outpatient settings limits the generalizability of our findings to other settings (e.g. inpatient) or phases of the illness (e.g. prodromal, residual). Our study did not include a breakdown of depressive versus bipolar types within the schizoaffective group. Elevated depression scores and the relative infrequency of mood stabilizing medication imply predominance of the depressive type. In addition, patients with bipolar disorder were not included and thus the study could not address whether the same pattern of cognitive and social cognitive and neural deficit holds true across the schizophrenia-bipolar disorder continuum. In addition, it should be noted that diagnostic criteria for schizoaffective disorder changed with the introduction of DSM 5, which requires the presence of a major mood episode for the majority of the total duration of the active and residual portions of the illness ([@bb0020]). This means that our study data and previous findings may not apply fully to patients meeting new diagnostic requirements.

In conclusion, the present data reveal extensive overlap between patients with schizoaffective disorder and schizophrenia across demographic, symptomatic, cognitive and social cognitive functioning as well as in socially relevant brain network structures. These results do not undermine the clinical importance of mood disorder in the schizophrenia spectrum, but do support further critical analysis of the scientific value of traditional diagnostic distinctions and the possible amalgamation of psychosis syndromes.
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[^1]: *Note*. PANSS, Positive and Negative Syndrome Scale; SPHS, Social and Psychiatric History Schedule.

[^2]: F test from one-way ANOVA (non-significant).

[^3]: Chi-squared test (non-significant).

[^4]: *t*-Test (non-significant).

[^5]: *t*-Test (*P* \< .05).

[^6]: Chi-squared test (*P* \< .05).

[^7]: Anti-Parkinsonian medication data based on 37 schizophrenia and 26 schizoaffective disorder patients.

[^8]: Medication data based on 38 schizophrenia and 26 schizoaffective disorder patients.

[^9]: *Note*. MCCB, MATRICS Consensus Cognitive Battery; MSCEIT, Mayer--Salovey--Caruso Emotional Intelligence Test; WASI, Wechsler Abbreviated Scale of Intelligence; WRAT-4, Wide Range Achievement Test - Fourth Edition.

[^10]: Significantly different from schizophrenia patients.

[^11]: Significantly different from schizoaffective patients.

[^12]: Mann-Whitney test significantly different from control group (*P* \< .05).

[^13]: *t*-Test significantly different from control group (*P* \< .001).

[^14]: *F*(2, 132) = 18.72.
